Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
12 Giugno 2023 - 10:01PM
Mechelen, Belgium;
12 June 2023,
22:01 CET; Galapagos NV
(Euronext & NASDAQ: GLPG) today
announced that during its meeting of
12 June
2023, the Board of Directors
co-opted Dr. Susanne
Schaffert as
non-executive independent
Director. Dr. Schaffert
replaces Dr. Rajesh Parekh
who stepped down
on 10 June
2023.
After an extraordinary 27-year career at Novartis in various
global roles, including commercialization, market access, investor
relations, business development & licensing, acquisitions and
company integration, Dr. Schaffert retired in 2022 as President of
Novartis Oncology and Member of the Novartis Executive Committee.
In that role, Dr. Schaffert ran a global $15 billion business
across 80 countries, accelerating the internal product pipeline
with six new clinical programs, multiple global launches, and
making the first CAR-T therapy, Kymriah®, commercially available in
36 countries, including the US, Europe, and Japan.
Dr. Schaffert is also a member of the Board of Directors of
Incyte Corporation (NASDAQ: INCY) and Novo Holdings A/S, and a
member of the Novo Advisory Group (NAG) and the Executive Education
Board of St. Gallen Business School.
“On behalf of the Galapagos’ Board of Directors, I am very
pleased to welcome Susanne to our Board,” said Dr. Paul Stoffels1,
CEO and Chairman of Galapagos. “Susanne brings a wealth of R&D,
regulatory and commercial expertise in oncology, and more
specifically in CAR-T therapy. Her operational experience, global
network and understanding of the competitive landscape in oncology
will offer important perspectives and strategic input to our Board
as we continue our work to deliver transformational medicines to
patients.”
“I am very honored to join the Board of Directors of Galapagos,”
commented Dr. Susanne Schaffert. “I look forward to contributing to
the company’s mission to pioneer for patients and accelerate
science and innovation to address important unmet needs.”
“The Board and I also want to sincerely thank Dr. Rajesh Parekh
for his invaluable contributions and commitment as former Chairman
and member of the Board of Directors during his 19-year tenure. As
a co-founder and member of the Board of Directors of Galapagos in
the early days, I had the opportunity to work with Raj, and I have
always greatly appreciated his leadership and insights in building
out the company throughout the years,” concluded Dr. Paul Stoffels,
CEO and Chairman of Galapagos.
About GalapagosGalapagos is a fully integrated
biotechnology company united around a single purpose: to transform
patient outcomes through life-changing science
and innovation for more years of life and quality of
life. We focus on the key therapeutic areas of immunology and
oncology, where we have developed a deep scientific expertise in
multiple drug modalities, including small molecules and cell
therapies. Our portfolio comprises discovery through to
commercialized programs and our first medicine for rheumatoid
arthritis and ulcerative colitis is available in Europe and Japan.
For additional information, please visit www.glpg.com or
follow us on LinkedIn or Twitter.
Contacts
Media
relations contactMarieke
Vermeersch +32 479 490
603 media@glpg.com |
Investor
relations contact Sofie Van Gijsel +1 781 296
1143Sandra Cauwenberghs +32 495 58 46 63 ir@glpg.com |
Forward-looking statementsThis press
release includes forward-looking statements, all of
which involve certain risks and uncertainties. These statements are
often, but not always, made through the use of words or phrases
such as “will,” “continue,” “forward,” and any similar
expressions. These statements include, but are not limited to,
statements regarding the appointment of a new director. Any
forward-looking statements in this press release are based on our
management’s current expectations and beliefs, and are not
guarantees of future performance. Forward-looking statements may
involve unknown and known risks, uncertainties and other factors
which might cause our actual results, performance, or achievements
to be materially different from any historic or future results,
performance, or achievements expressed or implied by such
statements. These risks, uncertainties and other factors
include, without limitation, the risk that we may not be able to
realize the expected benefits from the appointment of the new
director. A further list and description of these risks,
uncertainties and other factors can be found in our filings and
reports with the Securities and Exchange Commission (SEC),
including in our most recent annual report on Form 20‐F filed with
the SEC, as supplemented and/or modified by any other filings and
reports that we have made or will make with the SEC in the future.
Given these risks and uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements. In
addition, even if our results, performance, or achievements are
consistent with such forward-looking statements, they may not be
predictive of results, performance, or achievements in future
periods. These forward-looking statements speak only as of the date
of publication of this press release. We expressly disclaim
any obligation to update any forward-looking statements in this
press release, unless required by law or regulation.
1 Throughout this press release, ‘Dr. Paul
Stoffels’ should be read as ‘Dr. Paul Stoffels, acting via Stoffels
IMC BV’
Grafico Azioni Galapagos NV (NASDAQ:GLPG)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Galapagos NV (NASDAQ:GLPG)
Storico
Da Giu 2023 a Giu 2024